Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.
Arecor Limited, located on the Cambridge Science Park, was established to provide formulation solutions to pharmaceutical and biotech companies developing drugs, vaccines, medical devices and diagnostics.
Telephone: +44 (0)1223 426 060
Address: Chesterford Research Park Little Chesterford Saffron Walden
Post Code: CB10 1XL
Country: United Kingdom
Membership Type: Corporate 21-50